Dual targeted therapy shows promise in mestastatic clear cell renal cell carcinoma
The combination of lenvatinib plus everolimus improved progression-free survival in the LenCabo trial, but toxicity must be carefully assessed
Adjuvant immunotherapy improves overall survival in renal-cell carcinoma
Updated results from the KEYNOTE-564 trial confirm the role of pembrolizumab after surgery
Study shows that immunotherapy initiation at the end of life has increased over time
In US, the trend was more frequently seen at very low-volume and nonacademic centers than at high-volume and academic centers